June2016

Thailand’s economy expected to grow 2.5 percent in 2016

by Mridha Shihab Mahmud - Jun 29, 2016

News Hour: Thailand’s economy is expected to grow by 2.5 percent in 2016, after growing 2.8 percent last year. While the global economy has been weakening and exports have been slowing, strong fundamentals and ample fiscal...
Phase III study shows Roche’s Actemra/RoActemra maintained steroid-free remission in people with Giant Cell Arteritis (GCA)

by Rafiuzzaman Sifat - Jun 29, 2016

News Hour: Roche (SIX: RO, ROG; OTCQX: RHHBY) announced positive results from the Phase III study known as GiACTA, which evaluated Actemra®/RoActemra® (tocilizumab) in people with giant cell arteritis (GCA). The study met its primary and...
Roche receives EU approval of Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer

by Rafiuzzaman Sifat - Jun 29, 2016

News Hour: Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission has approved the use of Avastin® (bevacizumab) in combination with Tarceva® (erlotinib) for the first-line treatment of adult patients with unresectable advanced, metastatic...
Roche’s Gazyvaro approved in Europe in combination with bendamustine for people with previously treated follicular lymphoma

by Rafiuzzaman Sifat - Jun 29, 2016

News Hour: Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission has approved Gazyvaro® (obinutuzumab) in combination with bendamustine chemotherapy followed by Gazyvaro maintenance in people with follicular lymphoma who did not respond or...
Roche employees raise funds for vulnerable children in over 90 communities around the world

by Rafiuzzaman Sifat - Jun 29, 2016

News Hour: Roche (SIX: RO, ROG; OTCQX: RHHBY) employees in 70 countries and 141 sites come together to participate in the 2016 Roche Children’s Walk, which takes place on the International Day of the African Child....
The new cobas e 801 module, helping hospitals meet the demand for increased diagnostic testing

by Rafiuzzaman Sifat - Jun 29, 2016

News Hour: Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that its new, dedicated high-volume testing immunoassay solution, the cobas e 801 module, is now available for countries accepting the CE Mark. As diagnostic laboratories evolve to...
Roche’s marketing applications for review of OCREVUS® (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA

by Rafiuzzaman Sifat - Jun 29, 2016

News Hour: Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Medicines Agency (EMA) has validated the company’s Marketing Authorisation Application (MAA) of OCREVUS® (ocrelizumab) for the treatment of relapsing multiple sclerosis (RMS) and primary...
Promising data from next generation alk/ros1 inhibitor in advanced non-small cell lung cancer

by Rafiuzzaman Sifat - Jun 29, 2016

News Hour: Pfizer Inc. (NYSE:PFE) announced encouraging new data from a Phase 1/2 study of lorlatinib, the proposed generic name for PF-06463922, Pfizer’s investigational, next-generation ALK/ROS1 tyrosine kinase inhibitor. The study showed clinical response in patients...
Data from phase 1b trial investigating utomilumab (a 4-1bb agonist) in combination with a checkpoint inhibitor

by Rafiuzzaman Sifat - Jun 29, 2016

News Hour: Pfizer Inc. (NYSE:PFE) announced results from a Phase 1b trial of Pfizer’s investigational immunotherapy agent utomilumab (the proposed non-proprietary name for PF-05082566), a 4-1BB (also called CD137) agonist, in combination with pembrolizumab, a PD-1...
A mother’s mission to help prevent another life lost to menb

by Rafiuzzaman Sifat - Jun 29, 2016

News Hour: One moment Patti Wukovits was preparing for her daughter’s high school graduation, and the next moment she was watching her fight for her life for 9 days in the intensive care unit. In 2012,...

« Previous 1 2 3 4 Next »

June2016

Thailand’s economy expected to grow 2.5 percent in 2016

Phase III study shows Roche’s Actemra/RoActemra maintained steroid-free remission in people with Giant Cell Arteritis (GCA)

Roche receives EU approval of Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer

Roche’s Gazyvaro approved in Europe in combination with bendamustine for people with previously treated follicular lymphoma

Roche employees raise funds for vulnerable children in over 90 communities around the world

The new cobas e 801 module, helping hospitals meet the demand for increased diagnostic testing

Roche’s marketing applications for review of OCREVUS® (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA

Promising data from next generation alk/ros1 inhibitor in advanced non-small cell lung cancer

Data from phase 1b trial investigating utomilumab (a 4-1bb agonist) in combination with a checkpoint inhibitor

A mother’s mission to help prevent another life lost to menb

Facebook

Twitter